AGI hits losses of $1.5m, but says trials are on track

IRISH pharmaceutical company AGI Therapeutics has seen its first half losses widen by about $1.5 million (€1.05m).

However, the company, added that the clinical trials programme for its lead treatment for irritable bowel syndrome — Rezular — remains on track.

For the first six months of this year, the Dublin-headquartered pharmaceutical firm reported a pre-tax loss of $8.94m (€6.33m).